DarioHealth FY26 Q2 net loss narrows 39% to $7.92 million; revenue falls 3.6% to $5.18 million

Reuters2026/08/11 10:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

DarioHealth posted a GAAP net loss of USD 7.92 million, narrowing 39% from the year-earlier quarter.
Revenue fell 3.6% to USD 5.18 million, pressured by lower pharma-channel revenue tied to a prior-year non-recurring item.
GAAP gross margin rose 6.5 percentage points to 61.7%, helped by lower technology amortization, lower hosting costs, and an IEEPA tariff refund.
R&D expense dropped 43.6% to USD 2.1 million, reflecting post-merger integration efficiencies and AI-driven headcount reductions.
Commercial updates included 181 customers at quarter-end, a Fortune 50 employer award covering 100,000+ eligible employees, and a GLP-1 program launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DarioHealth Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-093645), on August 11, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

DarioHealth FY26 Q2 net loss narrows 39% to $7.92 million; revenue falls 3.6% to $5.18 million

You may also like

Crypto prices